ArticlePloS one2025
Molecular simulation-based investigation of thiazole derivatives as potential LasR inhibitors of Pseudomonas aeruginosa.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combining Triazole Scaffold Repurposing and Generative Transformer Architecture for Structure-Based Inhibitor Design Targeting the LasR Quorum Sensing Receptor ofPharmaceuticals (Basel, Switzerland) · 2026Article
- From code to cure: computational identification of LasR inhibitors to combat quorum sensing in P. aeruginosa.Molecular diversity · 2026Article
- Uncovering the bactericidal potential of extract and multi-targeting phytochemicals from Mirabilis longiflora L. leaves against multidrug-resistant Pseudomonas aeruginosa and Bacillus cereus.Scientific reports · 2026Article
- Correction: Molecular simulation-based investigation of thiazole derivatives as potential LasR inhibitors of Pseudomonas aeruginosa.PloS one · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa (P. aeruginosa), a very resilient pathogen, demonstrates a diverse array of virulence factors, the expression of which is closely linked to the quorum sensing(QS) mechanism, which facilitates cell-cell interaction. Quorum sensing (QS) inhibition is a promising strategy for combating bacterial infections. LasR, a transcriptional factor that controls the mechanism of QS in P. aeruginosa, is a promising target for therapeutic development, because a lot of research has been done on its structure. It has already been established that thiazoles and their compounds have anti-QS potential against P aeruginosa. The study aims to identify new LasR quorum sensing inhibitors (QSIs) derived from novel thiazoles utilizing a structure-based virtual screening technique using the ZINC database. A complete set of 800 molecules (a novel thiazole derivative library) were docked inside the active region of the LasR receptor before being screened using pharmacokinetic and toxicology studies. Among the derivatives that were examined, compounds D_152, D_153, and L_331 were selected as potential inhibitors of LasR in P. aeruginosa and further studied to obtain a crucial understanding of the binding interactions that take place between inhibitor ligands and LasR. The findings indicated that the pharmacophoric characteristics of the derivative D_152 were comparable to those of the reference thiazole molecule (TC). Moreover, the molecular docking investigations showed that derivative D_152 and reference compound TC both fit the LasR protein's active area well. Furthermore, TC and D_152's amino acid interaction graphs with LasR and CviR are nearly identical. Furthermore, compound D_152's ability to engage with the LasR binding site through the dissolution of the protein's dimer was demonstrated by molecular dynamics modeling tests conducted over a 50 ns time span, demonstrating its function as a LasR antagonist. Additionally, Density Functional Theory (DFT) study was conducted on compound D_152 in order to determine the electron density of a molecule. According to the research findings, the recently produced thiazole derivative (D_152) has the potential to be used as a QSI against the LasR receptor, which would speed up the fight against the pathogenicity of P. aeruginosa that is resistant to multiple drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.